Abivax S.A. — 2023 Annual Report (Form 20-F)
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a separate fourth-quarter report; the filing does not provide a clear standalone Q4 income statement or cash-flow summary. Financial statements are audited and prepared under IFRS, in euros.
Business context and reporting period
Abivax is a clinical-stage biotechnology company with no approved products and no product sales. Its lead candidate, oral obefazimod, is being studied for moderately to severely active ulcerative colitis (UC); Phase 3 induction and maintenance trials were underway. The company also planned a Phase 2b Crohn’s disease (CD) trial and research on follow-on compounds. Abivax’s thesis is that obefazimod enhances miR-124, potentially regulating inflammation through multiple pathways.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Operating income | €4.6 million, primarily research tax credits and subsidies | €4.6 million |
| Research and development expense | €103.2 million | €48.3 million |
| Sales and marketing expense | €6.4 million | None reported |
| General and administrative expense | €22.4 million | €7.5 million |
| Operating loss | €127.4 million | €64.8 million |
| Net financial income (loss) | (€20.4 million) | €4.1 million |
| Net loss | €147.7 million | €60.7 million |
| Cash used in operating activities | €97.1 million | €53.9 million |
| Cash and cash equivalents at year-end | €251.9 million | €27.0 million |
No product revenue or profit margin is reported; the company remains loss-making and does not provide a meaningful product gross margin. Cash and cash equivalents plus other short-term investments were approximately €260.9 million at year-end. Total assets were €327.1 million and shareholders’ equity was €196.0 million. Financial liabilities were reported at €77.0 million on the balance sheet; the company’s contractual-obligations discussion reports €78.3 million of financial debt obligations, using a different presentation and scope.
Financing cash flow was €335.3 million, principally reflecting the February 2023 share issue and October 2023 U.S. IPO, partly offset by debt repayments and interest. The IPO generated approximately €202.0 million net proceeds. Management estimated that available resources, the €25.0 million Kreos/Claret tranche drawn in March 2024, and expected €4.5 million 2023 research tax-credit reimbursement would fund forecast cash requirements into Q4 2025, through anticipated UC Phase 3 induction readouts. This estimate depends on management assumptions and planned spending.
Material changes versus the prior year
- Net loss increased €87.0 million, or 143%, as R&D spending more than doubled with progression of UC Phase 3 trials; G&A and new sales and marketing costs also rose.
- Operating cash use increased €43.2 million, or 80%. The year-end cash increase was primarily supported by equity issuance and debt financing, not operating cash generation.
- FY 2023 had no goodwill impairment charge, compared with €13.6 million in 2022. Abivax stopped the ABX196 program in 2023 after freezing its development in 2022; €18.4 million of goodwill remained allocated to obefazimod.
- Net financial loss shifted from income in 2022 to a €20.4 million loss in 2023, including €8.9 million of royalty-certificate interest expense, foreign-exchange losses, financing costs and debt-extinguishment effects.
- Abivax raised €130.0 million gross in February and €223.3 million gross in its October U.S. IPO. Shares outstanding rose to 62,928,818 at December 31, 2023, including treasury shares.
Outlook, financing, and key risks
- Clinical milestones stated in the filing: management expected UC induction-trial top-line data in Q1 2025 and maintenance data in Q1 2026; CD Phase 2b enrollment was planned for Q3 2024, with top-line results expected in H2 2026. These were forward-looking expectations, not guaranteed outcomes.
- Debt and collateral: the Kreos/Claret facility permits up to €75 million across three tranches, with the second €25 million drawn after year-end. Its lenders have first-ranking security over principal assets, including obefazimod intellectual property, bank accounts and receivables. Heights provided €35 million of convertible notes in 2023 and may provide additional financing subject to market-based conditions. Covenants, repayment obligations, conversion and potential dilution are material risks.
- Royalties: royalty certificates entitle holders to 2% of future worldwide obefazimod net sales, capped at €172 million. A separate licensing agreement with academic institutions may also require royalties; the filing says those royalties are uncapped.
- Going concern and capital needs: management concluded that substantial doubt about the company’s ability to continue as a going concern had been alleviated beyond 12 months from issuance, based on financing and cash-flow assumptions. Abivax expects continuing losses and says additional capital may be required; funding shortfalls could delay or reduce development.
- Clinical and commercial risks: Phase 3 success, safety, regulatory approval, patient enrollment, manufacturing and supply, reimbursement, market adoption and competition remain uncertain. Earlier-stage results do not predict Phase 3 outcomes; Abivax has no approved product and depends heavily on obefazimod.
- Controls and unusual items: management reported material weaknesses in internal control over financial reporting and ineffective disclosure controls as of year-end; remediation was incomplete. Share-based compensation expense was €8.2 million, and the former CEO received a €1.2 million departure indemnity.
- Other exposures: Abivax relies on third-party manufacturers and clinical research organizations, reports foreign-currency exposure and does not routinely hedge it, and identified two non-material cybersecurity incidents at clinical-trial sites in 2023. No material legal proceedings were reported.
Most important facts for investors to verify
- Actual UC Phase 3 enrollment, trial conduct, safety findings and final induction and maintenance results versus the filing’s expected timelines.
- Cash burn and runway against actual R&D spending, tax-credit receipts, financing availability and any revised clinical plans.
- Ability to satisfy debt covenants and draw remaining Kreos/Claret or Heights financing; repayment terms, collateral exposure and potential share dilution.
- Accounting and cash-flow implications of royalty certificates, including the 2% sales royalty and the separate uncapped academic royalty obligations.
- Progress and effectiveness of internal-control remediation, including whether the identified weaknesses result in reporting delays or misstatements.
- Share-based compensation, outstanding convertible instruments, warrants and free-share awards, and their potential dilution.